Multiple Myeloma Market Insights Highlighting Growth Opportunities Through 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Multiple Myeloma Market In 2026 And 2030?

The multiple myeloma market size has experienced strong growth in recent years. Projections indicate it will expand from $28.05 billion in 2025 to $30.25 billion in 2026, registering a compound annual growth rate (CAGR) of 7.9%. The growth during this historical phase is attributable to several factors: an escalating prevalence of hematologic cancers, the swift integration of chemotherapy agents, a surge in diagnostic imaging utilization, the expansion of hospital-centric treatment infrastructure, and the advent of first-generation immunomodulatory drugs.

The multiple myeloma market size is projected to experience substantial expansion in the upcoming years, with its value expected to reach $41.39 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.2%. This anticipated growth during the forecast period can be attributed to several factors such as progress in targeted therapies, an increasing need for stem cell transplants, wider adoption of precision medicine applications, an expanding clinical trials pipeline, and the increased use of monoclonal antibody therapies. Noteworthy trends during this period include the accelerated development of novel immunotherapies, a greater integration of monoclonal antibodies into treatment regimens, the rising acceptance of minimally invasive diagnostic techniques, the expansion of stem cell transplantation procedures, and an enhanced emphasis on combination therapies to achieve improved patient outcomes.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12163&type=smp

What Key Factors Are Affecting The Multiple Myeloma Market Demand?

The growing incidence of multiple myeloma is anticipated to drive the expansion of the multiple myeloma market in the future. This condition is a form of cancer originating in plasma cells, which are a type of white blood cell. Factors contributing to the rise in multiple myeloma cases include age, genetic predispositions, obesity, exposure to radiation, and various other health conditions. Treatment for multiple myeloma aims to impede its progression and alleviate associated symptoms. For example, projections released in February 2025 by the American Cancer Society, a US-based voluntary health organization, foresee approximately 36,110 new multiple myeloma cases and about 12,030 associated deaths in the United States during 2025, impacting both men and women. Consequently, the heightened occurrence of multiple myeloma is fueling the expansion of the multiple myeloma market.

How Is The Multiple Myeloma Market Segmented Across Different Segment Categories?

The multiple myeloma market covered in this report is segmented –

1) By Treatment: Medications, Radiation Therapy, Stem Cell Transplant, Other Treatments

2) By Diagnosis: Blood Tests, Bone Marrow Biopsy, Urine Tests, Imaging Tests

3) By Disease Type: Active Multiple Myeloma, Smoldering Multiple Myeloma

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

Subsegments:

1) By Medications: Immunomodulatory Drugs (IMiDs), Proteasome Inhibitors, Monoclonal Antibodies, Corticosteroids, Chemotherapy Agents

2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Radioisotope Therapy

3) By Stem Cell Transplant: Autologous Stem Cell Transplant (ASCT), Allogeneic Stem Cell Transplant

4) By Other Treatments: Supportive Care, Clinical Trials And Experimental Therapies

What Trends Are Influencing Changes In The Multiple Myeloma Market?

Key players in the multiple myeloma market are prioritizing the development of innovative treatments, including CAR T-cell therapy, to achieve a competitive advantage. CAR T-cell therapy, or Chimeric Antigen Receptor T-cell therapy, is an immunotherapy technique where a patient’s T cells are genetically altered to produce a chimeric antigen receptor, allowing them to identify and attack particular cancer cells. An example is the approval received in December 2023 by Bristol Myers Squibb, a US biopharmaceutical firm, for Abecma. This marked Abecma as the first CAR T-cell therapy to be used earlier in patients with relapsed or refractory multiple myeloma (RRMM) who have previously had at least two treatments. Abecma functions as a B-cell maturation antigen (BCMA)-directed CAR T-cell immunotherapy. This approval was granted following an interim analysis of the KarMMa-3 Phase 3 study, which showed a notable improvement in median progression-free survival (mPFS) and an elevated overall response rate (ORR) for the Abecma treatment group.

Which Organizations Play A Role In The Multiple Myeloma Market Landscape?

Major companies operating in the multiple myeloma market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Janssen Global Services LLC, Celgene Corporation, Biogen Inc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Karyopharm Therapeutics Inc., Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Xencor Inc., Oncopeptides AB, BeiGene Ltd., TG Therapeutics Inc.

Get The Full Multiple Myeloma Market Report:

https://www.thebusinessresearchcompany.com/report/multiple-myeloma-global-market-report

Which Region Holds The Highest Market Share In The Multiple Myeloma Market?

North America was the largest region in the multiple myeloma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple myeloma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Multiple Myeloma Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/multiple-myeloma-global-market-report

Browse Through More Reports Similar to the Global Multiple Myeloma Market 2026, By The Business Research Company

Disability Insurance Market Report 2026

https://www.thebusinessresearchcompany.com/report/disability-insurance-global-market-report

Pet Healthcare Market Report

https://www.thebusinessresearchcompany.com/report/pet-healthcare-global-market-report

Pet Diabetes Care Market Report

https://www.thebusinessresearchcompany.com/report/pet-diabetes-care-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795